Posted in

Long-Acting Lenacapavir for HIV Prevention Arrives in Africa

•Posted inMedical Updates
Cost breakdown of medical PG abroad for Indian MBBS graduates in the UK, US, and Australia

First doses of lenacapavir, an innovative long-acting drug for lenacapavir HIV prevention, have been delivered to Zambia and Eswatini. Approximately 1,000 doses of Gilead Sciences Inc.’s drug arrived in these African nations last Thursday. This pivotal delivery marks the initial rollout under a significant U.S. initiative. It aims to supply the twice-yearly injectable pre-exposure prophylaxis (PrEP) to countries with a high prevalence of the Human Immunodeficiency Virus (HIV).

Expanding Lenacapavir HIV Prevention Access in Africa

Zambia and Eswatini each received about 500 doses. Furthermore, Gilead is actively working to secure regulatory approval for distribution across other sub-Saharan African countries identified as high-burden regions. Notably, the African continent remains the epicenter of the AIDS pandemic, making these prevention efforts crucial. Therefore, expanding access to effective interventions like lenacapavir is a public health priority. For those interested in understanding the broader implications and management of infectious diseases, consider the Postgraduate Diploma in Infectious Disease.

Conversely, the United States will not provide U.S.-funded doses to South Africa, despite its having the world’s highest HIV burden. Around 8 million people, or one in five adults, live with HIV in South Africa. Jeremy Lewin, a senior U.S. State Department official, explained this decision on Monday, encouraging South Africa, with its significant means, to fund doses for its own population. This exclusion arises amidst past political clashes between former U.S. President Donald Trump and South African President Cyril Ramaphosa, including disputes over aid and false claims of genocide.

The U.S. Strategy for Global HIV Prevention

The U.S. State Department initially announced its plan in September to introduce lenacapavir to market at cost in high-burden HIV countries. The overarching goal is to reach two million people over three years. Under this scheme, Gilead has agreed to offer the long-acting drug without profit to the Global Fund and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). These organizations represent leading global HIV/AIDS initiatives. Earlier, Lewin confirmed agreements with 12 recipient countries, though he did not publicly identify them.

Gilead CEO Daniel O’Day further mentioned on a media call that the company collaborates with other governments. They are partnering with the Global Fund and PEPFAR, and have submitted marketing authorizations through countries such as Rwanda, Tanzania, and Botswana, alongside several others. This strategy emphasizes broad international cooperation. However, previous foreign aid cuts by former President Trump, including halting grants by USAID, had impacted the availability of critical prevention drugs, especially for vulnerable communities like gay men and sex workers.

Understanding Lenacapavir’s Role in HIV Prevention

Lenacapavir represents a significant scientific advancement in HIV prevention, offering a twice-yearly injectable pre-exposure prophylaxis (PrEP). This long-acting formulation provides a convenient and highly effective alternative to daily oral pills, potentially improving adherence rates. The World Health Organization (WHO) has recommended lenacapavir as an additional HIV prevention choice, highlighting its potential to increase PrEP uptake globally. Moreover, clinical trials have demonstrated nearly 100% protection against HIV acquisition, making it a powerful tool in the fight against the epidemic. India is also poised to play a crucial role in the global access strategy, with Indian manufacturers receiving voluntary licenses from Gilead to produce generic versions for low- and middle-income countries. For healthcare professionals focused on sexual health and its challenges, the Certification Course In Sexual And Reproductive Health offers valuable insights.

Frequently Asked Questions

Q1: What is lenacapavir and how is it administered?

A: Lenacapavir is a long-acting antiretroviral drug developed by Gilead Sciences. It is administered as a twice-yearly injection for HIV prevention, offering a convenient alternative to daily oral pills.

Q2: Which countries are initially receiving lenacapavir under the U.S. scheme?

A: Zambia and Eswatini are the first countries to receive lenacapavir doses under the U.S. scheme, with approximately 500 doses delivered to each nation.

Q3: Why is South Africa not receiving U.S.-funded doses despite its high HIV burden?

A: The U.S. will not provide funded doses to South Africa due to past political tensions and encourages South Africa to fund its own supply, given its significant financial capacity.

References

  1. First doses of HIV prevention drug lenacapavir delivered to Zambia, Eswatini – ETHealthworld.
  2. Gilead Sciences Update on Access Strategy for Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries – Gilead.com.
  3. WHO recommends injectable lenacapavir for HIV prevention – WHO.int.
  4. Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low and Lower Middle Income Countries – Gilead.com.
  5. Game-changing HIV prevention shot may soon be made in India – TimesofIndia.IndiaTimes.com.
  6. Can India Deliver on the Promise of Lenacapavir? – ORF.in.
  7. India’s HIV Prevention Boost: Dr. Reddy’s, Hetero to Supply Gilead’s Lenacapavir at ₹3,500 for Twice-Yearly Dose – TheLogicalIndian.com.
  8. WHO recommends lenacapavir as twice yearly injection to help prevent HIV – MedicalNewsToday.com.
  9. Lenacapavir breakthrough: India at the heart of global HIV strategy – PolicyCircle.org.
  10. One shot every six months: India could change HIV prevention forever – Business-Standard.com.
  11. Hetero and Gilead Sciences Partner to Expand Global Access to Lenacapavir for HIV Treatment and Prevention – BioPharma-APAC.com.
  12. Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership – ContagionLive.com.
  13. UNAIDS welcomes new WHO guidelines on Lenacapavir – UNAIDS.org.
  14. IAS statement: IAS calls for global access as Gilead announces lenacapavir licensing – IASociety.org.
  15. Gilead Statement on New WHO Implementation and Testing Guidelines for Twice-Yearly Lenacapavir for HIV Prevention – Gilead.com.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.